Skip to content

US · IMMP · BIOTECHNOLOGY

Immutep Limited (IMMP) intrinsic value and stock valuation

$3.11as of 2026-11-21 · Mkt cap 56.86M

Data updated · price as of 2026-11-21

Strongly undervaluedIC value is more than 50% above the price. The exact IC value, upside and the fair-value band are available with Pro.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

Immutep Limited DCF and intrinsic value

InvestorsCraft values IMMP with the Chepakovich two-stage DCF model — currently rated strongly undervalued. How the model works · Run your own DCF prefilled from IMMP’s statements →

Immutep Limited Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Biotechnology Sydney, NSW 2000 immutep.com

How the business is doing

Fiscal 2011–2025, USD

Revenue
$5.04M-7.6% 5y CAGRd
20112025
Net income
-$-61.43M
20112025
Free cash flow
-$-62.1M
20112025
Total equity
$143.6M+34% 5y CAGRd
20112025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2011–2025, USD
20252024202320222021
Revenue$5.04M$3.84M$3.51M$170K$3.86M
Operating income-$-126.42M-$-88.1M-$-77.69M-$-33.94M-$-31.68M
Net income-$-61.43M-$-42.72M-$-39.9M-$-32.21M-$-29.9M
EPSd-$-421.97K-$-355.67K-$-443.04K-$-373.54K-$-494.79K
Operating cash flow-$-62.05M-$-34.82M-$-35.88M-$-30.23M-$-17.64M
Capital expenditure-$-50K-$-930K-$-50K-$-20K-$-20K
Free cash flow-$-62.1M-$-35.75M-$-35.93M-$-30.25M-$-17.66M
Total assets$157M$201.6M$147.5M$102.2M$82M
Total debt$1.63M$1.59M$1.23M$1.73M$2.82M
Net debt-$-65.78M-$-160.2M-$-122.19M-$-78.26M-$-57.31M
Total equity$143.6M$189.5M$136.5M$94.1M$73.3M
Cash and short-term investments$129.7M$181.9M$123.4M$80M$60.1M
Income statement
20252024202320222021
Revenue$5.04M$3.84M$3.51M$170K$3.86M
Cost of revenue$61.4M$41.6M$2.06M$2.06M$17.2M
Gross profit-$-56.37M-$-37.7M$1.44M-$-1.89M-$-13.37M
Research and development expenses$61.4M$41.6M$28.8M$31.3M$17.2M
Selling, general and administrative expenses$8.64M$8.85M$14.1M$7.21M$6.28M
Other expenses$0.00$0.00$2.06M-$-6M-$-5.22M
Operating expenses$70.1M$50.4M$44.9M$32.6M$18.3M
Cost and expenses$131.5M$92M$81.2M$34M$35.5M
Interest income$5.25M$3.88M$940K$220K$110K
Interest expense$20K$30K$20K$90K$10K
Depreciation and amortization$2.13M$2.01M$1.86M$1.84M$1.89M
Ebitda-$-62.88M-$-44.54M-$-39.57M-$-31.87M-$-17.77M
Operating income-$-126.42M-$-88.1M-$-77.69M-$-33.94M-$-31.68M
Total other income/expenses, net$65M$45.4M$37.8M$1.63M$1.77M
Income before tax-$-61.43M-$-42.72M-$-39.9M-$-32.21M-$-29.9M
Income tax expense$0.00$0.00$0.00$0.00$0.00
Net income-$-61.43M-$-42.72M-$-39.9M-$-32.21M-$-29.9M
Weighted average shares outstanding$145.6M$120M$90.1M$86.2M$60.4M
Weighted average diluted shares outstanding$145.6M$120.1M$90.1M$86.2M$60.4M
Balance sheet
20252024202320222021
Cash and short-term investments$129.7M$181.9M$123.4M$80M$60.1M
Net receivables$10K$7.56M$7.97M$8.37M$6.12M
Inventory$0.00$0.00$0.00$0.00-$-5.66M
Total current assets$149.1M$191.4M$135M$90.8M$68.4M
Property, plant and equipment, net$570K$680K$470K$310K$310K
Goodwill and intangible assets$7.2M$8.24M$9.49M$10.6M$12.9M
Long-term investments$0.00$0.00$0.00$0.00$0.00
Total non-current assets$7.89M$10.2M$12.5M$11.4M$13.6M
Total assets$157M$201.6M$147.5M$102.2M$82M
Accounts payable$5.53M$3.79M$5.45M$2.87M$1.82M
Short-term debt$1.31M$230K$190K$170K$420K
Deferred revenue$0.00$0.00$0.00$0.00$0.00
Total current liabilities$12.8M$10.5M$9.77M$6.41M$5.34M
Long-term debt$310K$1.36M$1.04M$1.56M$2.61M
Deferred revenue, non-current$0.00$0.00$0.00$0.00$0.00
Total non-current liabilities$590K$1.57M$1.21M$1.68M$3.42M
Capital lease obligations$520K$630K$390K$280K$290K
Total liabilities$13.4M$12.1M$11M$8.09M$8.76M
Common stock$535.1M$542.1M$446.3M$367.4M$313.4M
Retained earnings-$-444.08M-$-382.65M-$-339.93M-$-302.34M-$-274.64M
Accumulated other comprehensive income (loss)$52.7M$30.1M$30.1M$29M$34.5M
Total equity$143.6M$189.5M$136.5M$94.1M$73.3M
Total investments$62.3M$20.1M$0.00$0.00$0.00
Total debt$1.63M$1.59M$1.23M$1.73M$2.82M
Net debt-$-65.78M-$-160.2M-$-122.19M-$-78.26M-$-57.31M
Cash flow statement
20252024202320222021
Net income-$-61.43M-$-42.72M-$-39.9M-$-32.21M-$-29.9M
Depreciation and amortization$2.39M$2.26M$2.06M$2.06M$2.07M
Stock-based compensation$1.16M$1.8M$2M$1.49M$1.7M
Change in working capital-$-8.54M$3.46M$760K-$-1.56M-$-1.99M
Accounts receivable-$-2.52M$600K-$-1.61M-$-2.25M-$-2.83M
Inventory$0.00$0.00$0.00$810K$0.00
Accounts payable$0.00$0.00$3.27M$1.44M$1.38M
Net cash provided by operating activities-$-62.05M-$-34.82M-$-35.88M-$-30.23M-$-17.64M
Investments in property, plant and equipment-$-50K-$-930K-$-50K-$-20K-$-20K
Acquisitions, net$0.00$0.00$0.00$0.00$0.00
Net cash used for investing activities-$-38.53M-$-21.02M-$-30K-$-20K-$-20K
Common stock issued-$-160K$100.2M$80.1M$53M$43.3M
Common stock repurchased$0.00$0.00$0.00$0.00$0.00
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities-$-530K$95.2M$76M$50.3M$52.7M
Net change in cash-$-94.38M$38.4M$43.4M$19.4M$34.3M
Cash at end of period$67.4M$161.8M$123.4M$80M$60.6M
Operating cash flow-$-62.05M-$-34.82M-$-35.88M-$-30.23M-$-17.64M
Capital expenditure-$-50K-$-930K-$-50K-$-20K-$-20K
Free cash flow-$-62.1M-$-35.75M-$-35.93M-$-30.25M-$-17.66M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Immutep Limited

        Immutep Limited, a biotechnology company, engages in developing novel Lymphocyte Activation Gene-3 related immunotherapies for cancer and autoimmune diseases in Australia. Its lead product candidate is the eftilagimod alfa (efti or IMP321), a soluble LAG-3lg fusion based on LAG-3 immune control mechanism for the treatment of different types of cancers. The company's product pipeline also includes TACTI-004, which is in phase III clinical trial for the treatment of first line non-small cell lung cancer (1L NSCLC); TACTI-003, which is in phase IIb clinical trial to treat first line head and neck squamous cell carcinoma (HNSCC); INSIGHT-005 which is in phase I for metastatic urothelial carcinoma; TACTI-002, which in phase II trial for the treatment NSCLC and HNSCC; AIPAC-003, which is in phase II/III clinical trial to treat metatastic breast cancer; and EFTISARC-NEO, which is in phase II clinical trial for the treatment of soft tissue sarcoma. It also develops INSIGHT-003, which is in phase I trial 1L non squamous NSCL; INSIGHT-005 that is in phase I to treat metastatic urothelial cancer; IMP761, which is in phase I Trial to treat autoimmune disease; IMP731 for oncology and autoimmune diseases; and LAG525. Immutep has collaboration with Merck & Co., Inc., EOC Pharma, Novartis, and Laboratory Corporation of America Holdings. The company was formerly known as Prima BioMed Ltd and changed its name to Immutep Limited in November 2017. The company was incorporated in 1987 and is based in Sydney, Australia.

        CEO
        Marc Voigt
        Employees
        53
        Beta
        2.27

        Explore

        Frequently asked questions

        What is the intrinsic value of Immutep Limited (IMMP)?

        Immutep Limited (IMMP) is currently strongly undervalued based on the InvestorsCraft IC model — IC value is more than 50% above the price. The exact intrinsic value is available to Pro subscribers. How the IC value is calculated.

        Is IMMP undervalued?

        IMMP trades at a price of $3.11 (Nov 21, 2026): strongly undervalued — IC value is more than 50% above the price.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.